469, 570 and 645) were mutated to S or F, and the mutants were expressed both in insect and mammalian cells. We found that mutation in Y459 prevented protein expression; the Y469S and Y645S mutants lost their activity; while the Y570S, Y469F, and Y645F mutants retained function as well as cholesterol and bile acid sensitivity. We found that in the case of the Y413S mutant, drug transport was efficient, while modulation of the ATPase activity by cholesterol and bile acids was significantly altered. We suggest that the Y413 residue within a putative CRAC motif has a role in sterol-sensing and the ATPase / drug transport coupling in the ABCG2 multidrug transporter.
Mutations of the central tyrosines of putative Cholesterol Recognition
ABCG2 is an MDR half transporter, harboring only a single NBD and a single TMD, and must at least homodimerize to exert its proper transporter function [1] [2] [3] .
ABCG2 is expressed in many tissues, most abundantly in organs displaying barrier functions (brain, placenta, and intestine) where it influences the passage of hydrophobic or slightly negatively charged molecules, including numerous drugs and food constituents.
Therefore, ABCG2 can significantly influence the ADME-Tox (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties of drugs, especially the absorption from the intestine, penetration to the central nervous system through the blood-brain-barrier, or the elimination from the liver or kidney [3] [4] [5] [6] . Optimal activity of ABCG2 has been shown to be important in the regulation of serum urate levels, and polymorphic ABCG2 variants with decreased function or expression were shown to be associated with a higher risk of gout [7] [8] [9] .
Human ABCG2 is expressed in stem cells of various origins, where it provides a protective role under hypoxic conditions [10] . Overexpression of ABCG2 confers multidrug resistance to cancer cells [11] [12] [13] .
We and others have shown that both the ATPase and the transport activity of ABCG2 are significantly accelerated by cholesterol enrichment of "cholesterol poor" insect cell membranes; whereas cholesterol depletion of mammalian cells results in decreased ABCG2 function [14, 15] , implying that cholesterol is a major modulator of ABCG2 function.
Subsequent studies have shown that functional reconstitution of purified ABCG2 requires cholesterol, suggesting that it is in fact essential for ABCG2 activity [16] .
The mechanisms by which cholesterol-ABCG2 interactions translate into the observed changes of function, or the site(s) involved in cholesterol sensing have not been defined. There is no experimental evidence proving direct binding of cholesterol by ABCG2 and it is not known if ABCG2 recognizes cholesterol as a transported substrate, as shown for some related ABCG transporters [17, 18] . More probably, cholesterol is an allosteric modulator of the transporter, or may also have an indirect effect through influencing the biophysical properties of the lipid bilayer.
Previous studies have suggested that single amino acids can influence cholesterol sensing of ABCG2. Mutation of R482 to small amino acids (D, G, N, S, T) were shown to alter the cholesterol sensitivity [19] ; mutation of the leucines in the LxxL motif (potential steroid binding element (aa 555-558 [20] ) resulted in an apparent cholesterol insensitivity of ABCG2 in Sf9 membranes [19] . While these results may suggest that the mutated amino acids directly participate in cholesterol binding, they are not part of known motifs that characterize dedicated cholesterol binding regions. Many proteins that interact with cholesterol possess an amino acid consensus sequence termed "CRAC" (Cholesterol Recognition Amino acid Consensus) with the pattern (L/V-(X)(1-5)-Y-(X)(1-5)-R/K). The CRAC sequence was shown to be an essential determinant of cholesterol recognition in the peripheral-type benzodiazepine receptor, caveolin, the gp41protein of the HIV virus, or an integral outer mitochondrial membrane translocator protein [21] [22] [23] [24] . The length of a CRAC motif varies between 5-13 amino acids, however, only the first and last amino acids and the central tyrosine residue are conserved. Various mutational studies of the CRAC motifs of cholesterol binding proteins and cholesterol-regulated ion channels have demonstrated the crucial role of the central tyrosine in cholesterol binding [22, 23, 25] .
Given the modulatory effects of cholesterol on ABCG2 activity, we screened the amino acid sequence of the protein for CRAC motifs. We have identified five putative CRAC sequences, and changed the central tyrosines to define each motif's role in cholesterol-sensing.
Here we show that the CRAC motif containing tyrosine at position 413 in transmembrane helix 1, is involved in sterol sensing and the modulation of ATPase / transport coupling of the ABCG2 transporter.
2. Experimental procedures 2.1. Materials -Cholesterol-RAMEB (Randomly Methylated -Cyclodextrin) was a kind gift from Cyclolab Hungary. All other chemicals were purchased from Sigma (Sigma Aldrich, Hungary) unless stated otherwise.
2.2.
Plasmid constructs -For the expression of ABCG2 mutants in insect cells, baculovirus plasmids containing the appropriate mutant ABCG2 cDNAs were generated by PCR mutagenesis, as described earlier [26] . The list of primers used for mutagenesis is provided in the "Supplementary material". The PCR products were digested with PstI and NcoI enzymes and were ligated into the corresponding sites of the pAcUW21-L/wtABCG2 plasmid [27] . The base order of the constructs was confirmed by sequencing. The generation of the vector construct with the ABCG2-K86M mutant was described earlier [26] .
The plasmids for stable expression in mammalian cell lines were created by the ligation of the appropriate fragments from pAcUW21-L/ABCG2-Tyr mutant between the NotI-BamHI sites of the pSB-CMV-wtABCG2 plasmid [28] .
Cells and cell lines -Sf9 cells (Invitrogen, Life technologies) were grown in TNM-FH
insect cell medium complemented with 10 % FBS and 100 g/ml penicillin/100 U/ml streptomycin at 27 o C. HEK 293 cells were cultured in D-MEM medium containing 10 % FBS and 100 g/ml penicillin/100 U/ml streptomycin and 5 mM glutamin at 37 o C in 5% CO2. 
Generation of insect cells expressing ABCG2-Tyr mutants

Generation of HEK 293 cells stably overexpressing human ABCG2 and its Tyr
mutants -Cells were transfected using 3 l Fugene6 reagent (Promega) and 500 ng of the Sleeping Beauty pSB-ABCG2 plasmid DNA and 500 ng plasmid coding a transposase [29] . 48h post transfection the cells were cultured in 1 g/ml puromycin for 14 days. Cells overexpressing the highest amounts of the appropriate ABCG2 variant were sorted based on 5D3 labeling using FACSAria cell sorter (Becton Dickinson). In cholesterol depletion experiments we used the HEK 293 cell line stably expressing the R482G mutant established earlier [15] .
Membrane preparation -Isolation of membranes from Sf9 cells expressing human
ABCG2 or its Tyr mutants and the determination of membrane protein concentrations by the modified Lowry method were performed as described [30] . Besides control membranes prepared from untreated Sf9 cells, cholesterol pre-loaded membranes were also generated by co-incubation of the membranes with 0.25, 0.5, 1 or 2 mM cholesterol-RAMEB at 0 o C for 30 minutes prior to the final ultracentrifugation step of the membrane preparation procedure [15] .
2.7.
Detection of ABCG2 by Western blotting -Sf9 membranes or HEK 293 whole cells were suspended in sample loading buffer (62.5 M Tris HCl pH 6.8, 2 % SDS, 10 M EDTANa pH 6.8, 10 % glycerol, 2M urea, 0.14 mg/ml bromophenol blue, 100 M dithiothreitol).
Protein samples were separated on 7.5% Laemmli gels. Western blot analysis was performed as described earlier [26] , by using the BXP-21 monoclonal antibody in a 2,000x dilution, and a goat anti-mouse HRP-conjugated secondary antibody (10,000x dilution, Jackson Immunoresearch). 
2.9.
ATPase assay -Measurement of ATP hydrolysis was performed as described earlier [27] . The concentrations of test compounds used in the different experiments are indicated in the figure legends. Basal or drug-stimulated ATPase activities were compared to that measured in the absence of excess cholesterol. For the calculation of the KA values, the data were fitted with a non-linear dose response curve using the Origin 8.6 program. 
Vesicular uptake assay -The accumulation of 50 M
Statistical analysis of data -Statistical significance was assessed using paired
Student's t-test.
Results
Identification of potential CRAC motifs
Cholesterol sensor motifs are located in or near the membrane plane; therefore we restricted our analysis to the transmembrane domain of ABCG2. We identified five putative CRAC motifs in ABCG2 (Fig. 1) . Alignment of the corresponding regions of the human ABCG proteins revealed that three out of the five identified CRAC motifs are also present in other members of the human ABCG family (see Figure 1, 
Expression and ATPase activity of ABCG2 CRAC mutants in Sf9 insect cells
To analyze whether the putative CRAC motifs of ABCG2 influence cholesterol-sensing, we mutated the central tyrosines (Y413, 459, 469, 570 and 645) to Ser. The mutant proteins were expressed in Sf9 insect cells for functional measurements. All but one of the ABCG2 mutants were successfully expressed in Sf9 insect cells. Mutation of Y459 to S prevented the expression of the protein, precluding this mutant from further analysis ( Fig. 2A) .
Transport of substrates by ABCG2 is coupled to the hydrolysis of ATP. Measurement of the ATPase activity of the transporter is a well-established tool for the characterization of the activity of various mutant protein variants as well as for the screening of potential ABCG2-interacting compounds [5] . In order to determine the functionality and the cholesterol dependence of the CRAC mutant ABCG2 proteins, we measured their ATP hydrolytic capacity in isolated Sf9 insect cell membranes. We found that mutation of Tyr to Ser at position 469 or 645 resulted in the loss of ATP hydrolysis (even if the activity is corrected for the lower expression level of the Y469S mutant); while mutations in the other two positions apparently did not alter ABCG2 functionality, as both the Y413S and Y570S mutants showed a high level of ATPase activity, inhibited by a general ATPase inhibitor vanadate or the specific ABCG2 inhibitor Ko143 (Fig. 2B) .
In order to test if the inactivity of the Y469S and Y645S mutants was due to a specific loss of Tyr at this position, we also mutated these tyrosines to phenylalanines. We found that the Y469F and Y645F mutants were active (Fig. 2B) , indicating the importance of the phenyl ring, but not of a hydroxyl group at these positions.
Effects of cholesterol on the ATPase activity of the CRAC mutants
To test whether the CRAC tyrosine mutants are sensitive to the cholesterol content of the membranes, we characterized their ATPase activity in cholesterol-enriched insect cell membranes (Fig. 2C) . The cholesterol content of the insect cell membranes is relatively low, as compared to mammalian cells (5-8 g cholesterol/mg membrane protein vs. 50 g cholesterol/mg membrane protein in insect and mammalian cells, respectively). Co-incubation with cholesterol-loaded cyclodextrin complexes was shown to be a reliable experimental tool to increase the cholesterol contents of Sf9 membranes by up to 10-fold [15] . Using this approach, we have shown that the ATPase activity, especially the activation of ATP hydrolysis by transported substrates, in the case of the wild-type ABCG2 is greatly enhanced when the Sf9 membranes are enriched in cholesterol ( see [15] and Fig. 2C and Fig. 3A) .
We found that the basal ATPase activity of the Y469F, Y570S and Y645F mutants showed a moderate (approximately 20%, p<0.05) increase upon cholesterol addition, while the substrate stimulated ATP hydrolysis of the same mutants was significantly (50-100% increase, p<0.01) accelerated by cholesterol loading (Fig. 2C) . Therefore, these CRAC mutants behaved similarly to the wild-type ABCG2 protein. These results argue against a role of tyrosines 469, 570 and 645 in cholesterol sensing, suggesting that the corresponding regions are not functional CRAC motifs.
Conversely, we found that in the presence of cholesterol, the ATPase activity of ABCG2-Y413S was distinct from that of the wild-type transporter. In the case of Y413S, cholesterol resulted in a major (50 +/-8 %; p<0.01) enhancement of the basal ATP hydrolysis, which could be only slightly stimulated by the addition of prazosin or quercetin (Fig. 2B and C, and Fig.   4B ).
Next, we investigated whether other compounds which are known substrates of wtABCG2 also differently modify the Y413S-ATPase in the presence of cholesterol (Fig. 3) . Again, cholesterol potentiated the drug-stimulated ATPase activity of the wild-type (Fig. 3A) , as well as the 469F, the 570S and 645F mutants in the presence of several substrates (Supplementary Figure S1) . In contrast, the Y413S mutant had a significantly altered ATPase modulation pattern. Quercetin showed a 30 +/-6.5 % stimulation (p<0.01), whereas doxorubicin, flavopiridol, topotecan and SN-38 resulted in a concentration dependent inhibition (ranging from 26-70 %) of the ATPase activity of the protein (Fig. 3B, C, D and not shown) .
For a detailed analysis of the effects of cholesterol loading, the basal and drugstimulated ATPase activities of the wild-type and Y413S ABCG2 mutants were compared at increasing membrane cholesterol concentrations. As shown in Fig. 4A , the baseline ATPase of Y413S is activated by lower cholesterol concentrations than that of the wild-type protein, with a lower apparent half-maximum cholesterol activation concentration (KA value of 0.37 +/-0.27 mM ) as compared to the apparent affinity of the wild-type protein (KA for cholesterol of 0.70 +/-0.09 mM). In contrast, in the case of the substrate-stimulated ATPase activities, wtABCG2
showed higher sensitivity to cholesterol loading (Fig. 4B) : in the presence of quercetin the calculated KA value for cholesterol activation of the wild-type protein was 0.22 +/-0.20 mM, while, due to the low level of cholesterol activation a reliable KA for the Y413S protein could not be determined.
Altered bile acid sensitivity of the ABCG2-Y413S mutant
The experiments described above showed that both the baseline ATPase activity and also the stimulation of the baseline ATP hydrolysis by various drugs of the Y413S mutant differ significantly from that of the wild-type protein when excess cholesterol is present. We have recently found that bile acids (steroids formed from cholesterol in the liver) significantly decrease the high basal ATPase activity of wtABCG2, while they do not interfere with the ABCG2-mediated ATP hydrolysis measured in the presence of substrates [16, 19] . This phenomenon results in a significant (up to 5-7 fold) increase in the relative, substrate stimulated ATP hydrolysis, depending on the type of bile acids. In order to find out whether the active ABCG2 CRAC mutants have any alterations in their interactions with bile acids, we measured their ATPase activities in the presence of cholic acid, glycocholate and taurocholate.
We found that the ATPase activities of the 570S, 469F, 645F and wild-type ABCG2 variants were similarly modified by bile acids (data not shown). In contrast, we found major differences in the effects of bile acids on the ATPase activity of the Y413S mutant. Though the addition of bile acids decreased the baseline ATPase activity of this ABCG2 mutant (Fig. 5A) , bile acids also decreased ATP hydrolysis in the presence of substrates. Therefore the net result of bile acid effects was only a slight increase in the relative substrate stimulation of the Y413S mutant (Fig. 5B-D) .
Effects of cholesterol on the transport activity of the ABCG2 CRAC mutants in
Sf9 membranes
In addition to its effect on the ABCG2-ATPase activity, cholesterol has also been shown to significantly enhance the transport capacity of the protein -e.g. methotrexate transport by the wild-type ABCG2 was about 4-fold activated when the insect cell membrane vesicles were enriched in cholesterol [15] . To further analyze the consequence of the putative CRAC Tyr mutations on the cholesterol-sensing of ABCG2, we measured 3 H-methotrexate transport both in control and cholesterol-loaded Sf9 membrane vesicles. As documented in Fig. 6 , all the examined ABCG2 mutants, including Y413S, exhibited a methotrexate transport activity that, similarly to the wild-type transporter, was significantly (3-4 fold) enhanced by cholesterol loading of the membranes.
Expression and transport activity of ABCG2 CRAC mutants in HEK 293 cellseffect of cholesterol depletion
According to the presented results the baseline ATPase activity of the ABCG2-Y413S mutant showed a sterol sensitivity that significantly differed from that of the wild-type, while in the vesicular transport measurement the effect of cholesterol on this mutant did not differ from that measured for wtABCG2. In order to further characterize the "cholesteroldependence" of the CRAC mutant ABCG2 proteins, we generated mammalian HEK 293 cells stably expressing the Y413S, Y469F, Y570S and Y645F mutants. Western blotting confirmed successful expression of these proteins (data not shown). Moreover, labeling with the anti-ABCG2 5D3 antibody, which recognizes an extracellular epitope, indicated proper plasma membrane localization of these mutants ( Supplementary Fig. S2 ).
To characterize the effect of cholesterol on the ABCG2 transport function, we depleted the cholesterol content of the cells by co-incubation with cyclodextrin (RAMEB). This method decreases membrane cholesterol levels by about 25%, and was successfully used in earlier studies to define the effects of various cholesterol levels on ABCG2 function in mammalian cells [15, 33] . Previously we have demonstrated that mild cholesterol depletion of HEK 293 cells resulted in a decreased transport function of wtABCG2, while did not alter the localization of ABCG2 or the viability of the cells [15] .
For measuring ABCG2 transport activity, intracellular accumulation of Hoechst 33342 was followed in control and cyclodextrin-treated HEK 293 cells, expressing the wild-type and the CRAC mutant ABCG2 variants. As shown in Fig. 7 , all ABCG2 mutants, including Y413S, were able to actively transport Hoechst 33342, and cholesterol depletion significantly decreased the Hoechst 33342 transport activity of all the CRAC mutants similarly to wild-type ABCG2.
Putative CRAC mutants of ABCG2, including Y413S, effectively transport substrate drugs and protect HEK 293 cells against cytotoxic substrates
The differential effects of the transported substrates on the wild-type and the Y413S ABCG2 ATPase activity may reflect different transport properties. Still, we did not find any alteration of the transport capacity or the cholesterol sensitivity of the Hoechst 33342 transport in the CRAC mutants.
In order to further explore the relationship of altered drug-stimulated ATPase and transport activities, the transport of various fluorescent ABCG2 substrates was compared in HEK 293 cells overexpressing wtABCG2 and the Y413S mutant, respectively. No major difference was found in BODIPY-prazosin, Hoechst 33342, mitoxantrone and Pheophorbide A transport by any of the active mutants analyzed in this study (Table I) . Interestingly, in spite of its different behavior in the ATPase assay, the Y413S mutant also did not differ significantly from the wildtype protein, with respect to the transport of the above mentioned substrates.
Among the cytotoxic drugs, the Y413S mutant ABCG2 protein (similarly to the wild-type) was able to transport doxorubicin (Fig. 8A ) and provided protection against doxorubicin, SN-38, flavopiridol and topotecan, strongly indicating an active transport of these compounds by this mutant (Fig. 8B and Supplementary Fig. S3 ).
Discussion
Understanding the regulation of the expression and function of ABCG2 may have important implications with regard to the modulation the ADME-Tox parameters of drugs and xenobiotics, in anti-cancer therapies, as well as in the treatment of gout. Cholesterol has been shown to be an essential activator of ABCG2 function [14] [15] [16] , although the exact nature of the interaction between cholesterol and the transporter has not yet been defined. Also, the molecular determinants of cholesterol sensing by ABCG2 remain largely unknown [19, 20] . Cholesterol recognition amino acid consensus sequence (CRAC) motifs have previously been confirmed to be involved in cholesterol sensing of various proteins [21-25, 34, 35] . Site directed mutagenesis studies targeting conserved CRAC amino acids identified a large variety of protein-specific phenotypes. In the case of the HIV gp41 protein, CRAC mutations resulted in reduced cholesterol binding [35] ; mutant peripheral-type benzodiazepine receptor variants showed altered cholesterol transport [34] , while in ion channels the channel function was retained but regulation by cholesterol was abolished [25, 36] .
Here, we aimed to determine whether the CRAC motifs identified in the ABCG2 sequence play any role in the sterol sensing of the human ABCG2 multidrug transporter. We found five putative CRAC sequences located in or near the transmembrane helices of ABCG2 (Fig. 1) .
Based on the previous CRAC mutagenesis studies described above, we expected that mutation of a functional CRAC motif would modify the effect of cholesterol on ABCG2 function. We have approached this question by using a number of specific methods.
ABC transporters couple ATPase and transport activities to promote the transmembrane movement of their substrates. This complex enzymatic activity can be followed in several experimental systems. ABCG2 expressed in Sf9 membranes displays relatively high baseline ATPase activity that can be moderately stimulated by transported compounds. The low intrinsic cholesterol content of the insect cell membrane allows the systematic modulation of membrane cholesterol levels. Using this model system, we and others have shown that the substratestimulated ATPase activity of ABCG2 is significantly accelerated by cholesterol [14, 15] .
Cholesterol makes up to 20% of the total lipids in mammalian cell membranes. Partial cholesterol depletion can be achieved by using "empty" cyclodextrins, which has been shown to result in a decrease of ABCG2 transport activity [15, 33] . Using this repertoire of assays we aimed to determine the role of the identified five CRAC motifs in the cholesterol-sensitive functions of ABCG2.
We found that tyrosines of putative CRAC motifs predicted to be located in or near to the intracellular surface of ABCG2 (Fig. 1) are essential for protein expression and/or function. Tyr to Ser mutations at positions 459, 469 and 645 resulted in the loss of protein function, and the Tyr 459 to Ser mutation resulted in a complete loss of ABCG2 expression (Fig. 2) . Insect cells are cultured at 27 o C which has been shown to allow the expression of improperly folded proteins [37] . The fact that the Y459S mutant could not be expressed properly in insect cells suggests that the tyrosine at this amino acid position is crucial for the proper folding and processing of the protein and therefore might be an important determinant of ABCG2 structure.
Recently, the Y459C heterozygous mutation was reported to occur in patients with renal cancer [38] . Therefore further exploration of the effect of mutations to residue 459 in ABCG2 is warranted.
The Y469S and Y645S mutants could be expressed in comparable amounts to the wild-type protein, however, they were found to be non-functional (Fig. 2) . These results may be interpreted in two ways. First, these tyrosines may be important for proper function or, alternatively, these mutants may lose their cholesterol sensing capability. Interestingly, introduction of a phenyl residue at the same position was found to be compatible with normal ATPase and transport activity, as well as with cholesterol sensing, indicating that these regions are not functional CRAC motifs. Rather, Y469 and Y645, along with Y459, may be important for proper folding of ABCG2. Our experiments, in which we tested the conformation of the ABCG2 mutants by labeling them with the conformation sensitive anti-ABCG2 5D3 antibody, revealed that the Y469S and Y645S mutants have decreased 5D3 binding capacity (Supplementary Figure S4) . Therefore the loss of the activity of the Y469S and Y645S mutants is most probably due to their improper conformation and not by their altered cholesterol sensing.
Previously, the Y645F mutation has been found to be functional, although has shown slightly decreased Hoechst 33342 transport capacity [39] . Interestingly, we did not find any major alteration in the substrate recognition by this mutant. Even its Hoechst 33342 transport capacity did not differ significantly from that of the wild-type protein (Fig. 7) .
The other two tyrosines (Y413 and Y570) mutated in this study are located in or near the extracellular surface of the transmembrane domain. We found that changing these amino acids is well tolerable for ABCG2, resulting in fully active proteins. The Tyr 570 to Ser mutation did not alter protein expression either in Sf9 or in HEK 293 cells, and substrate recognition and cholesterol-sensing of this mutant was also similar to that of the wild-type transporter (Fig. 2 and 6 and Supplementary Fig. S1 ).
However, the Y413S mutant exhibited a distinct ATPase activity. This mutant showed a greatly increased baseline ATPase in the presence of low levels of added cholesterol (Fig. 4A) , revealing an increased cholesterol sensitivity, while no further activation of the ABCG2-413S ATPase could be achieved by administration of transported substrates regardless of the cholesterol content of the membrane. Moreover, potential substrates that are known to activate the wild-type ABCG2-ATPase, rather inhibited the ATPase activity of the Y413S mutant (Fig.   3 ). In addition to this altered cholesterol-sensing, the ATPase activity of the Y413S mutant also had an altered bile acid sensitivity, as this mutant was less sensitive to bile acids than the wildtype protein (Fig. 5) .
The nature of the relatively high baseline ATPase activity of the human ABCG2 transporter is still not clarified. One explanation is an intrinsic, partially uncoupled function of the protein, manifesting in a "futile" ATP hydrolysis, keeping this multidrug transporter alert for rapid export of potentially harmful compounds [40] . Another possibility is the presence of an endogenous transported substrate, potentially cholesterol, triggering ATP hydrolysis without the addition of exogenous compounds. In the case of the Y413S mutant, cholesterol may promote "uncoupling" of the ATP hydrolysis in the ABCG2 protein. Alternatively, if we consider the possibility that cholesterol is transported by ABCG2, the results could be explained by a higher affinity to cholesterol by the ABCG2-Y413S mutant, also observed in the case of the R482G mutant [15] . The cholesterol-dependent increase in the ATPase activity is similar to that observed for several transported substrates. If ABCG2 can transport cholesterol, our data can be interpreted to suggest that the Y413S mutant is a more efficient cholesterol transporter.
Unfortunately, experimental verification of cholesterol transport is difficult due to the lack of dedicated assays measuring ABCG2-mediated cholesterol transport. Tarling et al. [41] measured cholesterol efflux to HDL in ABCG1 and ABCG2 overexpressing cells, and found that, in contrast to ABCG1, ABCG2 is not able to transport cholesterol to HDL. Since ABCG2-mediated cholesterol transport has not been experimentally confirmed, we speculate that the "cholesterol-stimulated" ATPase activity of the ABCG2-Y413S mutant is a result of its differential sensitivity to the modulatory effect of cholesterol.
In contrast to these findings related to the ABCG2-ATPase activity, we did not find any significant alteration in the cholesterol sensitivity of the ABCG2-Y413S mediated transport either in insect cell vesicular transport, or mammalian whole cell transport assays. Active substrate transport by the Y413S mutant was clearly activated by cholesterol in both systems, and by all the compounds examined ( Fig. 6 and 7) . Moreover, the Y413S mutant protected the cells against toxic drugs similarly to the wild-type ABCG2. All these experimental data suggest that although the ABCG2-Y413S mutant has an altered cholesterol interaction, it is rather manifested in a partial uncoupling of the ATPase activity of the transporter in the absence of transported substrates.
Conclusions
Our study is the first detailed analysis of potential CRAC motifs within an ABC protein, and here we provide experimental data for various functional consequences of the mutations in these motifs in ABCG2. Surprisingly, none of the functional mutants, containing putative CRAC motifs analyzed here abolished the cholesterol-sensitivity of the transporter, although mutation of Y413 significantly affected cholesterol and bile acid interactions. These data suggest that Tyr 413 within a putative CRAC motif is most probably part of a sterol-dependent regulatory region of ABCG2 and may regulate the coupling of ATPase to transport activity. 
